The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of BCGP.
BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.
Target Audience: These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours to maintain their Board of Pharmacy Specialties (BPS).
Geriatric Specialty Recertification Literature Study Module 1A: CardiovascularActivity Number: 0204-9999-26-935-H01-P
Contact Hour(s): 5.00
Activity Type: Application BasedLearning Objectives
Mahé I, Carrier M, Mayeur D, et al; API-CAT Investigators. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med. 2025 Apr 10;392(14):1363-1373. doi: 10.1056/NEJMoa2416112. Epub 2025 Mar 29. PMID: 40162636.
- Learning Objectives:
- Describe the Apixaban Cancer Associated Thrombosis (API-CAT) trial by Mahé and colleagues
- Develop recommendations for the use of antithrombotic therapy in patients with cancer-associated thromboembolism
McGuire DK, Marx N, Mulvagh SL, et al; SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29. PMID: 40162642.
- Learning Objectives:
- Describe the Semaglutide Cardiovascular Outcomes Trial (SOUL) by McGuire and colleagues of oral semaglutide in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, chronic kidney disease, or both
- Develop recommendations for the use of oral semaglutide in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, chronic kidney disease, or both
Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, Get al; DapaTAVI Investigators. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation. N Engl J Med. 2025 Apr 10;392(14):1396-1405. doi: 10.1056/NEJMoa2500366. Epub 2025 Mar 29. PMID: 40162639.
- Learning Objectives:
- Describe the Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation (DapaTAVI) trial by Raposeiras-Roubin and colleagues
- Develop recommendations for the use of dapagliflozin in adults with severe aortic stenosis undergoing transcatheter aortic-valve implantation ( TAVI)
Hanlon P, Butterly E, Wei L, t al. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis. JAMA. 2025 Mar 25;333(12):1062-1073. doi: 10.1001/jama.2024.27402. PMID: 39899304; PMCID: PMC11791772.
- Learning Objectives:
- Describe the systematic review and network meta-analysis by Hanlon and colleagues of age and sex differences in the efficacy of newer glucose-lowering medications for type 2 diabetes mellitus
- Develop recommendations for the use of glucose-lowering medications in patients with type 2 diabetes mellitus taking into consideration age and sex
Sun M, Wang X, Lu Z, et al. Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diabetes Res Care. 2025 Jul 22;13(4):e004902. doi: 10.1136/bmjdrc-2025-004902. PMID: 40695613; PMCID: PMC12306345.
- Learning Objectives:
- Describe the study by Sun and colleagues comparing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with metformin in patients with type 2 diabetes mellitus
- Develop recommendations for pharmacotherapy for patients with type 2 diabetes mellitus
|
Geriatric Specialty Recertification Literature Study Module 1B: General GeriatricsActivity Number: 0204-9999-26-936-H01-P
Contact Hour(s): 5.00
Activity Type: Application BasedLearning Objectives
American Geriatrics Society Beers Criteria® Alternatives Panel; Steinman MA. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. J Am Geriatr Soc. 2025 Jul 23:10.1111/jgs.19500. doi: 10.1111/jgs.19500. Epub ahead of print. PMID: 40697073; PMCID: PMC12448428.
- Learning Objectives:
- Describe the updated 2025 American Geriatrics Society (AGS) Beers Criteria® for alternative treatments to selected medications in the 2023 AGS Beers Criteria® for potentially inappropriate medication use in older adults
- Develop recommendations for pharmacologic and nonpharmacologic alternative strategies to use instead of medications included in the American Geriatrics Society (AGS) Beers Criteria® for potentially inappropriate medication use in older adults
Garrison SR, Youngson ERE, Perry DA, et al. Bedtime vs Morning Antihypertensive Medications in Frail Older Adults: The BedMed-Frail Randomized Clinical Trial. JAMA Netw Open. 2025 May 1;8(5):e2513812. doi: 10.1001/jamanetworkopen.2025.13812. PMID: 40354050; PMCID: PMC12070236.
- Learning Objectives:
- Describe the BedMed-Frail study by Garrison and colleagues comparing bedtime with morning administration of antihypertensive medications in frail older adults with hypertension
- Develop recommendations for antihypertensive drug therapy for frail older adults with hypertension
Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI. Clin Infect Dis. 2025 Dec 20:ciaf462.
- Learning Objectives:
- Describe the 2025 clinical practice guideline from the Infectious Diseases Society of America (IDSA) on management and treatment of complicated urinary tract infection
- Develop recommendations for the treatment of patients with complicated urinary tract infection (UTI)
|
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.